Bioceres Crop Solutions Corp. (BIOX)
Total Valuation
BIOX has a market cap or net worth of $756.52 million. The enterprise value is $951.71 million.
Market Cap | 756.52M |
Enterprise Value | 951.71M |
Important Dates
The next estimated earnings date is Wednesday, May 8, 2024, after market close.
Earnings Date | May 8, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
BIOX has 62.83 million shares outstanding. The number of shares has decreased by -0.73% in one year.
Shares Outstanding | 62.83M |
Shares Change (YoY) | -0.73% |
Shares Change (QoQ) | +0.08% |
Owned by Insiders (%) | 51.09% |
Owned by Institutions (%) | 29.94% |
Float | 12.95M |
Valuation Ratios
The trailing PE ratio is 35.69 and the forward PE ratio is 10.07.
PE Ratio | 35.69 |
Forward PE | 10.07 |
PS Ratio | 1.68 |
Forward PS | 1.42 |
PB Ratio | 2.52 |
P/FCF Ratio | 111.52 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.70, with an EV/FCF ratio of 140.29.
EV / Earnings | 43.35 |
EV / Sales | 2.11 |
EV / EBITDA | 12.70 |
EV / EBIT | 17.05 |
EV / FCF | 140.29 |
Financial Position
The company has a current ratio of 1.24, with a Debt / Equity ratio of 0.79.
Current Ratio | 1.24 |
Quick Ratio | 0.85 |
Debt / Equity | 0.79 |
Debt / EBITDA | 3.16 |
Debt / FCF | 34.88 |
Interest Coverage | 1.75 |
Financial Efficiency
Return on equity (ROE) is 7.30% and return on invested capital (ROIC) is 9.08%.
Return on Equity (ROE) | 7.30% |
Return on Assets (ROA) | 2.70% |
Return on Capital (ROIC) | 9.08% |
Revenue Per Employee | $1.13M |
Profits Per Employee | $54,888 |
Employee Count | 400 |
Asset Turnover | 0.55 |
Inventory Turnover | 1.85 |
Taxes
In the past 12 months, BIOX has paid $2.00 million in taxes.
Income Tax | 2.00M |
Effective Tax Rate | 8.33% |
Stock Price Statistics
The stock price has increased by +14.58% in the last 52 weeks. The beta is 0.56, so BIOX's price volatility has been lower than the market average.
Beta (1Y) | 0.56 |
52-Week Price Change | +14.58% |
50-Day Moving Average | 13.11 |
200-Day Moving Average | 12.33 |
Relative Strength Index (RSI) | 42.74 |
Average Volume (30 Days) | 70,503 |
Short Selling Information
Short Interest | 291,181 |
Short Previous Month | 294,321 |
Short % of Shares Out | 0.46% |
Short % of Float | 2.25% |
Short Ratio (days to cover) | 2.73 |
Income Statement
In the last 12 months, BIOX had revenue of $450.32 million and earned $21.96 million in profits. Earnings per share was $0.35.
Revenue | 450.32M |
Gross Profit | 189.36M |
Operating Income | 53.23M |
Pretax Income | 23.95M |
Net Income | 21.96M |
EBITDA | 74.96M |
EBIT | 55.81M |
Earnings Per Share (EPS) | $0.35 |
Balance Sheet
The company has $41.44 million in cash and $236.64 million in debt, giving a net cash position of -$195.19 million or -$3.11 per share.
Cash & Cash Equivalents | 41.44M |
Total Debt | 236.64M |
Net Cash | -195.19M |
Net Cash Per Share | -$3.11 |
Equity / Book Value | 300.54M |
Book Value Per Share | 4.78 |
Working Capital | 75.18M |
Cash Flow
In the last 12 months, operating cash flow was $29.61 million and capital expenditures -$22.82 million, giving a free cash flow of $6.78 million.
Operating Cash Flow | 29.61M |
Capital Expenditures | -22.82M |
Free Cash Flow | 6.78M |
FCF Per Share | $0.11 |
Margins
Gross margin is 42.05%, with operating and profit margins of 11.82% and 4.88%.
Gross Margin | 42.05% |
Operating Margin | 11.82% |
Pretax Margin | 5.32% |
Profit Margin | 4.88% |
EBITDA Margin | 16.65% |
EBIT Margin | 12.39% |
FCF Margin | 1.51% |
Dividends & Yields
BIOX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 0.73% |
Shareholder Yield | 0.73% |
Earnings Yield | 2.90% |
FCF Yield | 0.90% |
Analyst Forecast
The average price target for BIOX is $20.33, which is 60.71% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $20.33 |
Price Target Difference | 60.71% |
Analyst Consensus | Strong Buy |
Analyst Count | 3 |
Revenue Growth Forecast (5Y) | 20.99% |
EPS Growth Forecast (5Y) | 52.86% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 7 |